新诊断多发性骨髓瘤患者肾脏结局:UK NCRI Myeloma XI 试验结果
该研究基于 UK NCRI Myeloma XI 试验,评估 2334 例新诊断多发性骨髓瘤患者基线与 12 个月肾功能变化。在 1450 例计划自体移植可评估患者中,14% 出现 eGFR 较基线下降≥25%,23.5% 改善,62% 无显著变化;非移植计划患者结果相似。肾功能改善与年龄<70 岁、男性、基线平均 eGFR<60 mL/min/1.73m²、基线游离轻链>1000 mg/L 及游离轻链缓解>90% 相关,与 M 蛋白缓解、移植或硼替佐米方案无关。
要点
- 当前治疗下新诊断 MM 患者 12 个月内肾功能显著下降比例较小。
- 基线游离轻链高且轻链缓解深者 eGFR 相对改善最大。
- 肾功能改善与 M 蛋白缓解、移植或硼替佐米方案无关。
核心结论
- 当前治疗下新诊断 MM 患者 12 个月内肾功能显著下降比例较小。
- 基线游离轻链高且轻链缓解>90% 者 eGFR 相对改善最大。
研究设计与样本
- UK NCRI Myeloma XI 试验中评估 2334 例新诊断 MM 患者基线与 12 个月肾功能。
- 排除严重急性肾损伤或需透析患者。
- 1450 例计划自体移植患者可评估 12 个月肾脏结局,884 例非移植计划患者可评估。
主要发现
- 计划移植可评估患者中 204 例(14%)eGFR 较基线下降≥25%,341 例(23.5%)改善,905 例(62%)无显著变化。
- 非移植计划可评估患者 12 个月肾脏结局与移植计划患者相似。
- 肾功能改善更常见于年龄<70 岁、男性、基线平均 eGFR<60 mL/min/1.73m²、基线游离轻链>1000 mg/L 和/或游离轻链缓解>90%。
- 肾功能改善与 M 蛋白缓解、移植或硼替佐米方案使用无关。
关键数值与推荐
- eGFR 下降≥25% 定义为显著下降。
- 基线平均 eGFR<60 mL/min/1.73m² 与肾功能改善相关。
- 基线游离轻链>1000 mg/L 与肾功能改善相关。
- 游离轻链缓解>90% 与肾功能改善相关。
临床怎么用
- 新诊断 MM 治疗中应关注基线游离轻链水平及轻链缓解深度以评估肾功能改善可能。
- 不应仅依据 M 蛋白缓解、是否移植或是否使用硼替佐米方案判断肾功能改善。
局限性
- 排除严重急性肾损伤或需透析患者,结果不适用于该人群。
- 仅评估基线与 12 个月两个时间点肾功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Renal injury is a common complication of multiple myeloma (MM) and is associated with adverse outcome. Despite this, the natural history of renal injury in patients with MM remains uncertain especially in the context of intensive therapy and novel therapies. To address the lack of data, we evaluated the renal function of 2334 patients from the UK National Cancer Research Institute Myeloma XI trial at baseline and at 12 months to assess renal function over time and the factors associated with change. Patients who had severe acute kidney injury or a requirement for dialysis were excluded. At 12 months of the 1450 evaluable patients planned for autologous transplantation; 204 (14%) patients had a decline in estimated glomerular filtration rate (eGFR) ≥25% from baseline, 341 (23.5%) had an improvement and 905 (62%) had no significant change in eGFR. Renal outcome at 12 months for the 884 evaluable patients who were not planned for transplant was similar. Improved renal function was more likely if patients were <70 years old, male, had an average eGFR <60 mL per minute per 1.73 m2 and a higher baseline free light chain level >1000 mg/L, and/or a free light chain response of >90%. It did not correlate with monoclonal-protein response, transplantation, or use of a bortezomib-based regimen. We show that with current therapies the proportion of patients who have a significant decline in renal function in the first 12 months is small. The greatest relative improvement in eGFR is seen in patients with high free light chain at baseline and a high light chain response. This trial was registered at http://www.isrctn.com as #49407852.
引用
- Rana R, Cockwell P, Drayson M, et al. Renal outcome in patients with newly diagnosed multiple myeloma: results from the UK NCRI Myeloma XI trial. Blood Adv. 2020. PMID: 33232472. doi:10.1182/bloodadvances.2020002872
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。